Brooks Life Science Systems announces new applications for Celigo® Imaging Cytometer
Poway CA, August 30, 2012 - Brooks Life Science Systems, a division of Brooks Automation, Inc. (Nasdaq: BRKS), today announced that its ongoing investment and development of the Celigo® Imaging Cytometer is bringing new capabilities to academic research, biopharmaceutical drug development and high-throughput and high-content screening
Celigo is a multi-application cell imaging cytometer able to perform high-content and high-throughput fluorescence and brightfield cellular imaging and analysis with minimal sample manipulation. Following the acquisition of the Celigo Imaging Cytometer product earlier this year, Brooks Life Science Systems has developed a number of new and improved applications for use in cell line generation and oncology research.
New applications include:
- Tumor growth analysis in drug screening: brightfield and fluorescence acquisition of tumorspheres with fluorescence & morphologic measurements
- Single colony verification: enumeration of colonies within a well for identification of single clones
- Cell migration measurement: assessment of wound healing via typical scratch assays
- Faster automated measurement of cell counting & confluency
- Improved reproducibility and reliability of embryoid body segmentation
Dr Suzanne Eccles, Reader in Tumor Biology at the Institute of Cancer Research, Sutton commented, “Celigo has been essential to our work validating 3D models of tumor growth, invasion and angiogenesis. We now have robust, high-throughput growth assays, with results for 96-well plates in minutes compared with standard automated microscopy-based image analysis, and we have been able to develop novel quantitative, measurements of tumor invasion.
“By using the Celigo in our drug discovery research we have more clinically relevant models for drug evaluation which are contributing to a reduction in the amount of in vivo testing being performed.”
Clint Haris, Senior Vice President, General Manager, Brooks Life Science Systems added, “Cell analysis is a fast moving field that requires versatile instrumentation capable of meeting challenging demands. The development of these new applications is ensuring that Celigo continues to meet the needs of our customers and highlights our commitment to supporting the field of cell analysis.”
Brooks Celigo is designed for the rapid image capture and processing of cells with minimum plate movements and sample disturbance. Proven with both adherent and non-adherent cell types, its high resolution image acquisition coupled with uniform, high contrast and even illumination allows identification of “every cell in every well”. Compatibility with SBS multi-well plates along with T25 and T75 culture flasks, a simplified workflow for all assays and enhanced software capabilities, enables the Celigo to be used in a broad range of applications.
For further information on the Celigo Imaging Cytometer please visit http://www.brooks.com/celigo
– Ends –
About Brooks Life Science Systems
Brooks Life Science Systems is a leading worldwide provider of automation and related solutions for compound and biological sample storage, management and analysis. The Company combines the specialist expertise of industry-renowned brands, REMP®, Nexus, and RTS, together with the extensive R&D and global service capabilities of Brooks Automation.
Brooks Life Science Systems partners with its customers, working as a trusted advisor from specification, to system installation and ongoing service and customer support. From standardized bench top systems to custom installations, Brooks has the largest installed base of automated storage systems and support network in the Life Sciences industry, with more than 180 systems across the globe including at the top 20 pharmaceutical and biotechnology companies.
As pioneers in automated storage, Brooks Life Science Systems continually focuses its R&D activities on providing innovative solutions to maintaining sample integrity and security during sample storage, handling, analyzing and processing applications. Solutions provided by Brooks are transforming the productivity and streamlining the workflow of scientists across a broad range of life science applications, including drug discovery and biobanking.
Brooks Life Science Systems is a division of Brooks Automation, Inc (NASDAQ: BRKS), a public listed company with headquarters in North America and operations throughout North America, Europe and Asia. For more information, please visit www.brooks.com.
About Brooks Automation, Inc.
Brooks is a leading worldwide provider of automation, vacuum and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. The Company’s technologies, engineering competencies and global service capabilities provide customers speed to market, and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market and through product development initiatives and strategic business acquisitions; the Company has expanded its reach to meet the needs of customers in the life sciences industry, analytical & research markets and clean energy solutions. Brooks is headquartered in Chelmsford, MA, with direct operations in North America, Europe and Asia. For more information, please visit www.brooks.com.
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include statements regarding future adoption of new technologies and our ability to develop further our business. Factors that could cause results to differ from our expectations and other risks that we have identified are described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release.
MEDIA CONTACT:
Brooks Life Science Systems team at College Hill Life Sciences
Tel: +44 20 7866 7858
Email: BLSS@collegehill.com
